(Q34762064)

English

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response (English)

1 reference

Europe PubMed Central

4 August 2017

Alzheimer's disease

0 references

Jeffrey L. Cummings

2

object named as

Jeffrey Cummings

1 reference

Europe PubMed Central

4 August 2017

Martin R. Farlow

5

object named as

Martin Farlow

1 reference

Europe PubMed Central

4 August 2017

author name string

Marwan Sabbagh

1

1 reference

Europe PubMed Central

4 August 2017

Daniel Christensen

3

1 reference

Europe PubMed Central

4 August 2017

Rachelle Doody

4

1 reference

Europe PubMed Central

4 August 2017

Liang Liu

6

1 reference

Europe PubMed Central

4 August 2017

Joan Mackell

7

1 reference

Europe PubMed Central

4 August 2017

Randi Fain

8

1 reference

Europe PubMed Central

4 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 June 2013

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

13

1 reference

Europe PubMed Central

4 August 2017

56

1 reference

Europe PubMed Central

4 August 2017

https://scigraph.springernature.com/pub.10.1186/1471-2318-13-56

0 references

Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Reviewing the role of donepezil in the treatment of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Donepezil for dementia due to Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Galantamine: additional benefits to patients with Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

7 July 2018

Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2318-13-56

21 January 2018

Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681558

26 October 2018

Identifiers

10.1186/1471-2318-13-56

1 reference

Europe PubMed Central

4 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34762064&oldid=1935941101"